SA Transcripts 162.58K Followers

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing October 22, 2026 1:00 PM EDT

Company Participants

Pravin Dugel - Executive Chairman, President & CEO

Conference Call Participants

Biren Amin - Piper Sandler & Co., Research Division

Presentation

Biren Amin

Piper Sandler & Co., Research Division

All right. Maybe we could get started. My name is Biren Amin. I'm one of the biotech analysts here at Piper Sandler. We've got a fireside webinar with Ocular Therapeutix this afternoon.

I'd like to welcome Dr. Pravin Dugel, their CEO and Chairperson.

Question-and-Answer Session

Biren Amin

Piper Sandler & Co., Research Division

So Pravin, welcome. A lot going on in the retina field. But maybe we could just step back and kind of calibrate where you are with AXPAXLI.…